Next Issue
Volume 13, June
Previous Issue
Volume 12, December
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
0.9
1.1
Journals
Hematology Reports
Volume 13
Issue 1
share announcement
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.

Hematol. Rep., Volume 13, Issue 1 (March 2021) – 6 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
4 pages, 532 KiB  
Case Report
BCR/ABL1 Fluorescence In Situ Hybridization Fusion Signals on Both Copies of Chromosome 22 in a Philadelphia-Masked Chronic Myeloid Leukemia Case: Implication for the Therapy
by Silvia Soriani, Valentina Guido, Giambattista Bertani, Clara Cesana, Valentina Motta, Gabriella De Canal, Elena De Paoli, Silvio Veronese, Emanuela Bonoldi and Lorenza Romitti
Hematol. Rep. 2021, 13(1), 8795; https://doi.org/10.4081/hr.2021.8795 - 24 Mar 2021
Viewed by 941
Abstract
The cytogenetic hallmark of Chronic Myeloid Leukemia (CML) is the presence of Philadelphia (Ph) chromosome, which results from a reciprocal translocation t(9;22)(q34;q11). In this report, we describe a CML patient with no evidence of Ph chromosome but trisomy of chromosome 8 as single [...] Read more.
The cytogenetic hallmark of Chronic Myeloid Leukemia (CML) is the presence of Philadelphia (Ph) chromosome, which results from a reciprocal translocation t(9;22)(q34;q11). In this report, we describe a CML patient with no evidence of Ph chromosome but trisomy of chromosome 8 as single cytogenetic abnormality and a typical e14a2 (b3a2) BCR-ABL1 fusion transcript. Fluorescence In Situ Hybridization (FISH) analysis revealed an uncommon signal pattern: the fusion signals were located on both copies of chromosome 22. During the course of the disease the appearance of the p.(Tyr315Ile) mutation was recorded. To the best of our knowledge this is the first Ph chromosome-negative CML case with e14a2 (b3a2) BCR-ABL1 transcript and p.(Tyr315Ile) mutation. Full article
3 pages, 563 KiB  
Case Report
Unusual Presentation of COVID-19 in a Child Complicated by Massive Acute Pulmonary Embolism and Lung Infarction
by Tahani Bin Ali, Ghaleb Elyamany, Maha Nojoom, Mohamed Alfaki, Hassan Alahmari, Abdulwahab Alharthi, Muwaffak Hijazi, Atif Alsahari, Fahad Alabbas and Abdulnasir Al-Otaibi
Hematol. Rep. 2021, 13(1), 8874; https://doi.org/10.4081/hr.2021.8874 - 12 Mar 2021
Cited by 2 | Viewed by 996
Abstract
The Novel Coronavirus 2019 (SARSCoV-2), which was first reported on in Wuhan, China, in late December 2019, causes a respiratory illness called COVID-19 Disease. COVID-19 is most likely causing a hypercoagulable state, however the prevalence of acute venothromboembolism is still unknown. Limited data [...] Read more.
The Novel Coronavirus 2019 (SARSCoV-2), which was first reported on in Wuhan, China, in late December 2019, causes a respiratory illness called COVID-19 Disease. COVID-19 is most likely causing a hypercoagulable state, however the prevalence of acute venothromboembolism is still unknown. Limited data suggest pulmonary microvascular thrombosis may play a role in progressive respiratory failure. Here, we report a case of a child with an unusual presentation of COVID-19 presented initially by dry cough without fever and complicated by massive acute pulmonary embolism and lung infarction and treated successfully by hydroxychloroquine and azithromycin, in addition to anticoagulant therapy. Full article
3 pages, 484 KiB  
Case Report
Heparin-Induced Thrombocytopenia and COVID-19
by Michelangelo Sartori and Benilde Cosmi
Hematol. Rep. 2021, 13(1), 8857; https://doi.org/10.4081/hr.2021.8857 - 12 Mar 2021
Cited by 13 | Viewed by 1027
Abstract
Heparin-induced thrombocytopenia (HIT) has not been included as a possible cause of thrombocytopenia in Coronavirus Disease 2019 (COVID-19) patients. We report a case of HIT in a patient with COVID-19 treated with heparin. A 78-year-old man was admitted to our hospital for acute [...] Read more.
Heparin-induced thrombocytopenia (HIT) has not been included as a possible cause of thrombocytopenia in Coronavirus Disease 2019 (COVID-19) patients. We report a case of HIT in a patient with COVID-19 treated with heparin. A 78-year-old man was admitted to our hospital for acute respiratory failure and acute renal failure due to SARS-CoV-2 infection; in intensive care unit, one 5000 IU heparin dose (day 0, platelet count 305,000/μL). On day 2, haemoglobin started to decrease and heparin was stopped. On day 10, platelet count was 153,000/μL and 5000 IU calcium heparin subcutaneously twice daily was started. The platelet further decreased, reaching 49,000/μL on day 17, and the patient was investigated for suspected HIT: an IgG specific chemiluminescence test for heparin-PF4 antibodies was positive and a femoral DVT was found at ultrasound. Argatroban was started, platelet count increased without any bleeding and thrombosis complication. Our experience shows that HIT may develop in heparin treated COVID-19 patients and should be included among the possible cause of thrombocytopenia in such patients. Full article
2 pages, 362 KiB  
Case Report
Hemorrhagic Cystitis: A Successful Outcome for a Challenging Complication in Stem Cell Transplant
by Sergio Pinzón Mariño, Samira Bakali Badesa, María Jesús Viso Soriano and Isabel Izquierdo Garcia
Hematol. Rep. 2021, 13(1), 8574; https://doi.org/10.4081/hr.2021.8574 - 12 Mar 2021
Cited by 1 | Viewed by 599
Abstract
Hemorrhagic cystitis (HC) secondary to BK polyomavirus (BKPyV) is a frequent complication related to allogenic stem cell transplantation. With an important morbidity and mortality, this disease doesn’t have a stablished standard treatment or prophylaxis strategies. At this moment, the supportive therapies approved to [...] Read more.
Hemorrhagic cystitis (HC) secondary to BK polyomavirus (BKPyV) is a frequent complication related to allogenic stem cell transplantation. With an important morbidity and mortality, this disease doesn’t have a stablished standard treatment or prophylaxis strategies. At this moment, the supportive therapies approved to treat included hyperhydration, forced diuresis and transfusion support. Cidofovir is a nucleotide analog of deoxycytidine monophosphate against DNA viruses and it has been described for the treatment of BKPyV-HC, but at this moment, is not a front-line therapy. We report a successful case after the use of Cidofovir without Probenecid. No adverse effect was developed under the treatment, and after 4 weeks of treatment, the patient achieved an excellent response. Full article
4 pages, 646 KiB  
Brief Report
Repeated Courses of Escalating Doses of Nivolumab in Refractory Hodgkin Lymphoma with Recurrent Relapses Post Allografting: A Safe and Effective Treatment Approach
by Panayotis Kaloyannidis, Eshrak Al Shaibani, Asif Moinnudin, Khalid Al Anezi and Hani Al Hashmi
Hematol. Rep. 2021, 13(1), 8780; https://doi.org/10.4081/hr.2021.8780 - 5 Mar 2021
Cited by 1 | Viewed by 609
Abstract
For patients with Hodgkin Lymphoma (HL) who experience relapse post allogeneic stem cell transplantation, limited treatment options exist, and the ultimate outcome is poor. Recently, the programmed cell death protein-1 (PD-1) inhibitors have shown remarkable efficacy in patients with refractory/relapsed HL, also demonstrating [...] Read more.
For patients with Hodgkin Lymphoma (HL) who experience relapse post allogeneic stem cell transplantation, limited treatment options exist, and the ultimate outcome is poor. Recently, the programmed cell death protein-1 (PD-1) inhibitors have shown remarkable efficacy in patients with refractory/relapsed HL, also demonstrating an acceptable safety profile. However, due to effects on T-cell activity, the use of PD-1 inhibitors post allografting may potentially increase the risk of treatment-emergent graft versus host disease. We herein report the clinical course of a patient who experienced multiple relapses of HL post allogeneic stem cell transplantation. He failed several treatment modalities but he responded to escalating doses of the PD-1 inhibitor nivolumab, given at two different treatment time points, also demonstrating minimal and easily manageable toxicity. Full article
3 pages, 80 KiB  
Case Report
The Effect of Tetrastarch Solution for Capillary Leak Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation: A Report of 2 Cases
by Yu-Ting Lin, Chun-Ying Wong, Tsung-Yen Chang, Chia-Chi Chiu, Yu-Chuan Wen and Tang-Her Jaing
Hematol. Rep. 2021, 13(1), 8750; https://doi.org/10.4081/hr.2021.8750 - 5 Mar 2021
Cited by 1 | Viewed by 646
Abstract
Capillary leak syndrome (CLS) is a severe complication of allogeneic hematopoietic stem cell transplantation (HSCT) characterized by weight gain, generalized edema, hypotension, and hypoalbuminemia. The primary pathogenesis is injury of the capillary endothelium resulting in a loss of intravascular fluid into the interstitial [...] Read more.
Capillary leak syndrome (CLS) is a severe complication of allogeneic hematopoietic stem cell transplantation (HSCT) characterized by weight gain, generalized edema, hypotension, and hypoalbuminemia. The primary pathogenesis is injury of the capillary endothelium resulting in a loss of intravascular fluid into the interstitial space. Treatment is limited to vascular endothelial growth factor withdrawal and systemic corticosteroids. We report two cases with CLS where weight gain, ascites, and hypotension developed after neutrophil engraftment following allogeneic HSCT. We obtained serial electrolytes, blood urea nitrogen, creatinine, and albumin from these patients. Ultrasound with Doppler tracing performed on both patients showed no reversal of portal venous flow. Issues addressed were the restoration of regular hydration by hydroxyethyl starch (HES) solutions, together with systemic corticosteroids and forced diuresis. Tetrastarch was administered 10 and 20 days, respectively. Both patients recovered without sequelae. CLS is a frequent complication after allogeneic HSCT. The effects of HES on CLS merit further consideration and prospective study. Full article
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-6
Previous Issue
Next Issue
Back to TopTop